A Study of LY3841136 in Healthy and Overweight Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

148 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-30

Study Completion Date

2024-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to 14 and 28 weeks for each participant and may include 7 and 19 visits in parts A and B, respectively.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3502970 in Healthy Overweight and Obese Participants

NCT05313802

Healthy Obese

COMPLETED PHASE1

A Study of LY3541105 in Healthy and Overweight Participants

NCT05380323

Overweight Healthy

COMPLETED PHASE1

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

NCT05841238

Healthy Obese

COMPLETED PHASE1

A Study of LY3841136 in Overweight and Obese Participants

NCT06345066

Obesity Overweight

COMPLETED PHASE1

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06230523

Obesity Overweight and Obesity

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3841136 (Part A)

Single ascending doses of LY3841136 administered subcutaneously (SC).

Group Type EXPERIMENTAL

LY3841136

Intervention Type DRUG

Administered SC.

LY3841136 (Part B)

Multiple ascending doses of LY3841136 administered SC.

Group Type EXPERIMENTAL

LY3841136

Intervention Type DRUG

Administered SC.

Placebo (Part A)

Placebo administered SC.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC.

Placebo (Part B)

Placebo administered SC.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3841136

Administered SC.

Intervention Type DRUG

Placebo

Administered SC.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential
* Have had a stable weight for the last 3 months
* Have a body mass index (BMI) in the range of 18.5 to 32 kilogram per square meter (kg/m²), both inclusive (in Part A) or a BMI in the range of 27 to 40 kg/m², both inclusive (in Part B)

Exclusion Criteria

* Are women who are lactating
* Have known allergies to related compounds of LY3841136 or any components of the formulation
* Have a history of significant atopy (severe or multiple allergic manifestations), or clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions
* Have been diagnosed with Type 1 or Type 2 diabetes mellitus
* Have a history of chronic medical conditions involving the heart, liver, or kidneys

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes